


# What Do You Know About the COVID-19 Variants?

*SARS-CoV-2 and its variants, if it doesn't end, we must know what we are defeating*

## **Threat of SARS-CoV-2 Variant**

## *To Our Society*




### ***Increases Transmissibility<sup>1)</sup>***

Most of the SARS-CoV-2 variants are more contagious than the wild-type. Delta variant, in particular, is even more transmissible than the other variants.

WHO Label	Reproduction no. relative to wild-type
Alpha	29%↑
Beta	25%↑
Gamma	38%↑
Delta	97%↑↑

## **To Our Immune System**



### **Reduces Neutralization<sup>2-6)</sup>**

Many cases were reported that SARS-CoV-2 variants can inhibit antibody neutralization, which may reduce vaccine efficacy/effectiveness.

## To Our Health



### ***Increases Severity/Hospitalization<sup>7,8)</sup>***

Patients infected SARS-CoV-2 variants showed more severe illness and are more likely to be hospitalized than patients infected with wild-type.

*Therefore,*


**“Differentiation of the wild-type from variants is essential for precise diagnosis and variants surveillance”**

Why Seegene?

Seegene's Complete Solution for SARS-CoV-2 Variants



## Seegene's Portfolio for SARS-CoV-2 Variants

Products	Allplex™ SARS-CoV-2 <b>Variants I</b> Assay*	Allplex™ SARS-CoV-2 <b>Variants II</b> Assay**	Novaplex™ SARS-CoV-2 <b>Variants IV</b> Assay	Novaplex™ SARS-CoV-2 <b>Variants V</b> Assay
	CE-IVD Marked	CE-IVD Marked	RUO	RUO
	SARS-CoV-2 Variants I <b>4</b> <ul style="list-style-type: none"><li>RdRP gene</li><li>HV69/70 del</li><li>E484K</li><li>N501Y</li></ul>	SARS-CoV-2 Variants II <b>4</b> <ul style="list-style-type: none"><li>W152C</li><li>K417N</li><li>K417T</li><li>L452R</li></ul>	SARS-CoV-2 Variants IV <b>3</b> <ul style="list-style-type: none"><li>L452R</li><li>P681R</li><li>K417N</li></ul>	SARS-CoV-2 Variants V <b>4</b> <ul style="list-style-type: none"><li>F490S</li><li>P681R</li><li>L452Q</li><li>L452R</li></ul>
<b>Alpha</b> (B.1.1.7)	✓	●	●	●
<b>Beta</b> (B.1.351)	✓	✓	✓	●
<b>Gamma</b> (P.1)	✓	✓	●	●
<b>Delta</b> (B.1.617.2)	●	✓	✓	✓
<b>Eta</b> (B.1.525)	✓	●	●	●
<b>Iota</b> (B.1.526)	✓	●	●	●
<b>Kappa</b> (B.1.617.1)	●	✓	✓	✓
<b>Lambda</b> (C.37)	●	●	●	✓

\* Available in the U.S. as Novaplex™ Variants I Assay (Research Use Only)

\*\* Available in the U.S. as Novaplex™ Variants II Assay (Research Use Only)

### Specimens/Samples

- Nasopharyngeal swab
- Bronchoalveolar lavage (BAL)

- Nasopharyngeal aspirate
- Sputum

- Oropharyngeal swab
- Saliva

**Seegene's complete solution for SARS-CoV-2 variants provides insight for proactive response against rapidly emerging variants**

## Seegene's Assays Provide Superior Values

### 1 Tube Solution for SARS-CoV-2 Variants



- Accurately detects SARS-CoV-2 variants with 1 tube assay
- Seegene's variants assays allow detection of the most widespread variants

### Flexible Application




- Compatible with various sample types such as nasopharyngeal swab/aspirate, saliva and sputum
- Extraction-free for swab and saliva

### Multiplex Real-time PCR




- Simultaneous detection and identification using real-time PCR
- Provides individual Ct value of multiple targets

### Streamlined Automated System




### Premium Solution for SARS-CoV-2 and Variants Analysis SG STATS




Variant trend monitoring

Real-time variant trend monitoring for targeted patient group by geography, age, etc.



Visual analytics of associated variants

Data visualization by combination of mutations



In-depth variant analysis

Ct-value available by vaccination, symptom and other researcher's preference

# Kick your Real-time PCR up a notch!

With Seegene's core proprietary technology and expertise, enhance your MDx products with incomparable performance and usability.



## Oligo Design

Oligo design technology for high multiplex PCR: **SG-InSilico™**

Enables rapid designing of high multiplex oligos using Seegene-developed algorithms and confidential variables



## Amplification

Highly specific amplification technology for high multiplex PCR: **DPO™**

Allows the implementation of high multiplex diagnostics with unparalleled specificity using Seegene's unique primer structure



## Target Detection

High multiplex target detection technology: **TOCE™**

Achieves accurate target signals by independently controlling multiple target signals for primer and probe annealing temperatures



## Quantitative Detection

High multiplex target detection & quantification technology: **MuDT™**

Broadens capacity for high multiplex target detection & quantification by enabling analysis of multiple Ct values in a single detection channel



## Interpretation

High multiplex signal processing technology: **DSP™**

Enables accurate reporting of target's positive or negative results through Seegene's proprietary signal processing algorithms

## Ordering Information

Product	Volume	Cat. No.
Allplex™ SARS-CoV-2 Variants I Assay	100 rxns*	RV10286X
	50 rxns	RV10287Y
Novaplex™ SARS-CoV-2 Variants I Assay	124 rxns	R-RV10286W
	50 rxns	R-RV10287Y
Allplex™ SARS-CoV-2 Variants II Assay	100 rxns*	RV10305X
	50 rxns	RV10306Y
Novaplex™ SARS-CoV-2 Variants II Assay	124 rxns	R-RV10305W
	50 rxns	R-RV10306Y
Novaplex™ SARS-CoV-2 Variants IV Assay	124 rxns	R-RV10315W
	50 rxns	R-RV10316Y
Novaplex™ SARS-CoV-2 Variants V Assay	124 rxns	R-RV10341W
	50 rxns	R-RV10342Y

Instrument	Cat. No.
CFX96™ Dx (2 modules)	1845097-IVD & 1841000-IVD
Seegene NIMBUS	65415-03
Seegene STARlet	67930-03
SEEPREP32™	SG71100
Maelstrom™ 9600	M9600
STARMag 96 X 4 Universal Cartridge Kit*	7443004JUC384
STARMag 96 X 4 Viral DNA/RNA 200 C Kit*	EX00013C
STARMag 96 ProPrep**	EX00009P EX00009T
STARMag 96 ProPrep C**	EX00017P
TANBEAD® Nucleic Acid Extraction Kit***	
OptiPure Viral Auto Tube	W665566
OptiPure Viral Bulk Plate	W665A10
SGRespi™ Pure ***	EX00023P EX00024P EX00025T

\* For use with Seegene NIMBUS and Seegene STARlet only,

\*\* For use with SEEPREP32™, \*\*\* For use with Maelstrom™ 9600

Not Available for Sale in the United States

## References

- 1) Campbell F, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Euro Surveill. 2021;26(24):2100509.
- 2) Cele S, et al. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature. 2021;593(7857):142-146.
- 3) Madhi S A, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021;384(20):1885-1898.
- 4) Dejnirattisai W, et al. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell. 2021;184(11):2939-2954.
- 5) Sheikh A, et al. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397(10293):2461-2462.
- 6) Stowe J, et al. Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant 2021 [Available from: <https://khub.net/documents/135939561/479607266/Effectiveness-of+COVID-19+vaccines+against+hospital+admission+with+the+Delta+%28B.1.617.2%29+variant.pdf?1c2f3463-3997-ed16-2a6f-14e5deb0b997!=1623689315431>]
- 7) Funk T, et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Euro Surveill. 2021;26(16):21100348.
- 8) Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing 16 2021 [Available from: [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/997414/Variants\\_of\\_Concern\\_VOC\\_Technical\\_Briefing\\_16.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/997414/Variants_of_Concern_VOC_Technical_Briefing_16.pdf)]



[www.seegene.com](http://www.seegene.com)

## Seegene Inc.

Seoul, Republic of Korea  
Tel : +82-2-2240-4000

E-mail : [info@seegene.com](mailto:info@seegene.com)

## CANADA

Toronto, Canada  
Tel : +1-800-964-5680  
E-mail : [canada@seegene.com](mailto:canada@seegene.com)

## MEXICO

México city, México  
Tel : +52-55-8848-9646  
E-mail : [mexico@seegene.com](mailto:mexico@seegene.com)

## MIDDLE EAST

Dubai, UAE  
Tel : +971-4-558-7110  
E-mail : [sgme@seegene.com](mailto:sgme@seegene.com)

## BRAZIL

Belo Horizonte, Brazil  
Tel : +55-31-25153003  
E-mail : [contato@seegenebrazil.com.br](mailto:contato@seegenebrazil.com.br)

## GERMANY

Düsseldorf, Germany  
Tel : +49-211-9943-4260  
E-mail : [sgg@seegene.com](mailto:sgg@seegene.com)

## ITALY

Genova GE, Italy  
Tel : +39-010-667-1796  
E-mail : [info@arrowdiagnostics.it](mailto:info@arrowdiagnostics.it)

## USA

California, USA  
Tel : +1-925-448-8172  
E-mail : [info@seegenetech.com](mailto:info@seegenetech.com)